Variability in CYP3A (CYP3A4/5) and P‐glycoprotein (human MDR1 gene product) activity
underlies interindividual differences in oral cyclosporine (CsA) bioavailability. Racial …

Abstract Objective Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A4 with a
narrow therapeutic index and large individual difference. CYP3A4* 1B is reported to be …

Cyclosporine A (CsA), mainly metabolized by cytochrome P450 (CYP) 3A, presents a wide
interindividual variability in its kinetics. CYP3A4 and CYP3A5 are members of the CYP3A …

Purpose: The mutation frequency of the CYP3A4* 18B genetic polymorphism is relatively
high in Asian populations. The influence of this polymorphism on the pharmacokinetics of …

Background: The cyclophilin A (CypA)‐cyclosporine (CsA) complex promotes immune
response. The variation at the CypA gene could explain CsA‐pharmacokinetics and clinical …

Abstract Intestinal cytochrome P 450 3A4 (CYP3A4) and P-glycoprotein (P-gp) both play a
vital role in the metabolism of oral cyclosporine (CsA). We investigated the genetic …

Cyclosporine and tacrolimus are immunosuppressive drugs largely used in renal
transplantation. They are characterized by a wide inter-individual variability in their …

Aim: Cyclosporine is a substrate of CYP3A and ABCB1. This study examined the role of
CYP3A and ABCB1 polymorphisms on cyclosporine pharmacokinetics in renal transplant …

Purpose There is a great deal of controversy regarding the clinical impact of genetic variants
in patients receiving cyclosporine (CsA) as immunosuppressant therapy. We have …